CDKL5 Knockout HAP1 Cell Line

The choice depends on whether you are studying CDKL5 (cyclin-dependent kinase-like 5, STK9)'s role as a CMGC-family kinase or modeling CDKL5 deficiency disorder (CDD, a severe neurodevelopmental encephalopathy). The Knockout line is the standard tool for asking whether CDKL5 is required for these processes — CDKL5 is a serine/threonine kinase with sequence similarity to MAPKs and CDKs but distinct substrate specificity, with characterized substrates including EB2 (microtubule plus-end protein), MAP1S, NDE1, AMPH1; CDKL5 has roles in dendritic spine maturation and synaptic function. Overexpression is useful for studying CDKL5 gain-of-function effects. For neurodevelopmental disease research, the EDITGENE CDKL5 Knockout in HAP1 enables study of CDKL5 biology. CDKL5 X-linked mutations cause CDKL5 deficiency disorder (CDD, formerly atypical Rett syndrome), a severe early-onset epileptic encephalopathy with intellectual disability. Rescue with wild-type, kinase-dead, or patient-derived CDKL5 mutations enables disease genotype-function studies. The knockout is valuable for studying CDKL5 biology and emerging CDKL5-targeted approaches including gene therapy (the CDKL5 gene therapy programs are in preclinical/early clinical development); ⭐ ganaxolone (Ztalmy) — FDA-approved 2022 for CDD seizures — does not directly target CDKL5 but addresses the disease symptom.

Primary applications: • CDKL5 kinase activity: phospho-EB2, phospho-MAP1S, phospho-NDE1 Western blot analysis. • CDD modeling: rescue with patient-derived CDKL5 mutations (kinase domain, C-terminal truncation) for genotype-function studies. • Gene therapy validation: critical genetic null background for testing CDKL5 gene therapy vectors in preclinical development. • Microtubule dynamics: in heterologous neural-relevant contexts, microtubule plus-end binding analysis. EDITGENE recommends this model for researchers investigating CDKL5 biology and CDKL5 deficiency disorder gene therapy development.

Yes. CDKL5 rescue experiments are critical for CDD gene therapy research: • Construct design: use a codon-modified CDKL5 sequence with a small C-terminal tag (FLAG, HA). CDKL5 has N-terminal kinase domain and C-terminal regulatory tail — preserve all elements. • Kinase-dead rescue: K42R mutation in the ATP-binding lysine abolishes catalytic activity. • CDD patient mutation rescue: kinase domain missense mutations (R59X, R134X, others) and C-terminal truncation mutations enable disease genotype-function studies. • Gene therapy validation: rescue with codon-optimized CDKL5 supports preclinical gene therapy vector validation. • Functional readout: rescue should restore CDKL5 substrate phosphorylation (phospho-EB2, phospho-MAP1S). HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.